<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.95104</article-id><article-id pub-id-type="publisher-id">ACM-30492</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190500000_18362959.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  直穿法置管腹透在高龄重症急性肾衰患者中的应用
  Acute Peritoneal Dialysis with Percutaneously Placed Catheter in Aged Intensive Care Patients with Acute Kidney Injury
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>铭新</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>黎明</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>凌云</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>金金</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蒋</surname><given-names>媛姣</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>贤忠</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>上海曲阳医院，上海</addr-line></aff><aff id="aff2"><addr-line>上海曲阳医院血透室，上海</addr-line></aff><aff id="aff3"><addr-line>复旦大学附属华山医院肾病科，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>05</month><year>2019</year></pub-date><volume>09</volume><issue>05</issue><fpage>685</fpage><lpage>690</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：评估直穿法置管腹透能否延长高龄重症急性肾衰患者的生存时间。方法：选取年龄大于75岁的重症监护患者出现急性肾衰的，予直穿法置管腹透为治疗组(A组)，基线特征匹配的未透析的为对照组(B组)。结果：两组各有2人入选。两组人在出现肾衰时的年龄、Charlson指数、血肌酐、尿量、平均动脉压、血钾、血碳酸氢盐、血白蛋白、C反应蛋白水平均无统计学差异。A组无穿刺出血、导管引流障碍等并发症。从诊断急性肾衰开始A、B组的中位生存时间分别是430、392小时(P = 0.0248)，从SOFA评分大于10开始A、B组的中位生存时间分别是418、323小时(P = 0.0499)，从SOFA评分大于14开始A、B组的中位生存时间分别是227、133 (P = 0.0303)。Cox比例风险分析显示腹透组的死亡风险比为0.397(P = 0.025)。结论：直穿法置管腹透可延长高龄重症急性肾衰患者的生存时间。
    Objective: To investigate whether acute peritoneal dialysis (PD) with percutaneously placed cath-eter can prolong survival time in aged intensive care patients (ICU) with acute kidney injury (AKI). Methods: Patients who aged over 75, having multiple organ dysfunction with AKI, being treated by acute PD with percutaneously placed catheter, were allocated in group A. Patients in group B were matched in baseline characteristics with group A. Results: The same baseline characteristics, in-cluding age, Charlson score, serum creatinine, urine output, mean arterial pressure, serum potas-sium, serum bicarbonates, serum albumin, CRP level, were noted in each group with 2 patients. Group A had no complications such as puncture bleeding and obstruction of catheter. Median sur-vival time after the diagnosis of AKI in group A and B was 430, 392 hours, respectively (P = 0.0248). Median survival time after SOFA score over 10 in group A and B was 418, 323 hours, respectively (P = 0.0499). Median survival time after SOFA score over 14 in group A and B was 227, 133 hours, respectively (P = 0.025). Conclusion: Acute PD with percutaneously placed catheter can prolong survival time in aged ICU patients with AKI. 
  
 
</p></abstract><kwd-group><kwd>腹透，急性肾损伤，经皮置管, Peritoneal Dialysis</kwd><kwd> Acute Kidney Injury</kwd><kwd> Percutaneously Placed Catheter</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>直穿法置管腹透在高龄重症急性肾衰患者中的应用<sup> </sup></title><p>刘玲<sup>1*</sup>，李铭新<sup>2#</sup>，杨黎明<sup>3</sup>，马凌云<sup>3</sup>，徐金金<sup>3</sup>，蒋媛姣<sup>3</sup>，袁贤忠<sup>3</sup></p><p><sup>1</sup>上海曲阳医院血透室，上海</p><p><sup>2</sup>复旦大学附属华山医院肾病科，上海</p><p><sup>3</sup>上海曲阳医院，上海</p><disp-formula id="hanspub.30492-formula7"><graphic xlink:href="//html.hanspub.org/file/10-1570936x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年5月3日；录用日期：2019年5月21日；发布日期：2019年5月28日</p><disp-formula id="hanspub.30492-formula8"><graphic xlink:href="//html.hanspub.org/file/10-1570936x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：评估直穿法置管腹透能否延长高龄重症急性肾衰患者的生存时间。方法：选取年龄大于75岁的重症监护患者出现急性肾衰的，予直穿法置管腹透为治疗组(A组)，基线特征匹配的未透析的为对照组(B组)。结果：两组各有2人入选。两组人在出现肾衰时的年龄、Charlson指数、血肌酐、尿量、平均动脉压、血钾、血碳酸氢盐、血白蛋白、C反应蛋白水平均无统计学差异。A组无穿刺出血、导管引流障碍等并发症。从诊断急性肾衰开始A、B组的中位生存时间分别是430、392小时(P = 0.0248)，从SOFA评分大于10开始A、B组的中位生存时间分别是418、323小时(P = 0.0499)，从SOFA评分大于14开始A、B组的中位生存时间分别是227、133 (P = 0.0303)。Cox比例风险分析显示腹透组的死亡风险比为0.397(P = 0.025)。结论：直穿法置管腹透可延长高龄重症急性肾衰患者的生存时间。</p><p>关键词 :腹透，急性肾损伤，经皮置管</p><disp-formula id="hanspub.30492-formula9"><graphic xlink:href="//html.hanspub.org/file/10-1570936x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-1570936x8_hanspub.png" /> <img src="//html.hanspub.org/file/10-1570936x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>高龄老年人常同时存在多种疾病，一旦患上重症，易出现急性肾损伤，从而生存时间缩短，病死率增加 [<xref ref-type="bibr" rid="hanspub.30492-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.30492-ref2">2</xref>] 。重症老年患者的急性肾损伤的体外肾替代治疗面临不少挑战，例如血流动力学不稳定，体外循环的抗凝风险，体外循环的血膜反应，体外循环感染的风险等等。而直接穿刺法置入腹透管行紧急腹透具有床旁可操作性，创伤小，对血流动力学影响小，不影响凝血与血小板功能，腹膜对炎性介质通透性高于普通的血滤膜等特点 [<xref ref-type="bibr" rid="hanspub.30492-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.30492-ref4">4</xref>] 。然而，采用这种方法救治老年重症急性肾损伤是否生存获益，尚未有文献报道，因而值得探讨。</p></sec><sec id="s4"><title>2. 对象与方法</title><p>入选于2018年1月至2019年4月期间因需要呼吸、循环支持而入住上海曲阳医院重症监护室、年龄大于75岁的男性病人。排除：慢性肾脏病3期以上，肝衰竭Child氏分级3级以上，脓毒症，晚期肿瘤，手术或创伤，中毒。</p><p>急性肾损伤诊断标准采用KDIGO-2012分级诊断标准 [<xref ref-type="bibr" rid="hanspub.30492-ref3">3</xref>] 。一旦诊断急性肾损伤，出现液体负荷增加、高血钾、代谢性酸中毒，根据病人或其委托代理人意愿签署知情同意书：如果愿意接受直穿法紧急腹透的，纳入治疗组；如果不愿意接受透析治疗，但基线特征与治疗组匹配，纳入对照组。本研究伦理获上海曲阳医院通过。</p><p>直接穿刺法置管：脐左旁正中线，避开腹壁浅动脉体表投影线周围3厘米，穿刺点在脐水平线下3厘米。采用箭牌双腔中心静脉穿刺套件(Arrow International Inc, USA)，Seldinger法穿刺采用B超实时引导，针尖位置在难以辨识时用注入3 ml生理盐水的方法示踪。针尖突破腹膜后置入0.032英寸J头导丝，在用7Fr扩张管预扩后，置入中心静脉导管。经此导管输入温生理盐水500 ml。确认导管在腹腔后，顺序用10Fr (3 &#215; 1.2 mm)、12Fr (4 &#215; 1.2 mm)扩张管(艾贝尔血透双腔管套件，广东百合医疗)扩张，最后置入14.5Fr带撕脱鞘扩张管(来自腹透Medcom套件，Baxter，USA)。经撕脱鞘内置入Tenchoff鹅颈腹透管。移去撕脱鞘，作皮下隧道引出腹透管，缝合穿刺口。</p><p>紧急腹透法：每2小时交换一次，每次1升腹透液，葡萄糖浓度按超滤目标选用1.5%、2.5%。钙离子浓度1.5 mmol/L。每天治疗时间12小时。治疗结束后干腹。</p><p>观察指标二大类：第一类腹透并发症：手术出血与血肿、导管功能障碍、腹腔脏器损伤、腹透相关性腹膜炎、血糖难以控制、蛋白营养恶化。第二类生存时间：诊断急性肾损伤后生存时间，SOFA [<xref ref-type="bibr" rid="hanspub.30492-ref5">5</xref>] 评分大于10、14分后生存时间。</p><p>统计学方法：连续变量用平均值&#177;标准差表示，偏态资料采用中位数表示，组间比较用配对t检验。生存资料用Cox比例风险模型检验。P &lt; 0.05为统计学显著差异。</p></sec><sec id="s5"><title>3. 结果</title><p>治疗组有2人。1人因心跳骤停入住ICU，基础疾病有2型糖尿病、痛风、冠心病、肺炎。另1人因脑梗死入住ICU，基础疾病有高血压、高血压性心脏病、心功能不全、慢支急性加重感染、贫血、消化道出血。</p><p>对照组匹配2人。1人因心跳骤停入住ICU，基础疾病有2型糖尿病、高血压、冠心病、房颤、慢阻肺急性加重。另1人因重症肺炎入住ICU，基础疾病有高血压、痛风、2型糖尿病、冠心病、急性冠脉综合征。</p><p>二组病人在急性肾损伤时的基线特征具有可比性，详见表1。治疗组顺序扩张情况图见图1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Baseline characteristics between 2 groups at the time of AK</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >治疗组</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >85.00 &#177; 9.90</td><td align="center" valign="middle" >84.50 &#177; 3.54</td><td align="center" valign="middle" >0.953</td></tr><tr><td align="center" valign="middle" >Charlson评分</td><td align="center" valign="middle" >7.50 &#177; 0.71</td><td align="center" valign="middle" >8.00 &#177; 1.41</td><td align="center" valign="middle" >0.699</td></tr><tr><td align="center" valign="middle" >血肌酐(μM)</td><td align="center" valign="middle" >306 &#177; 83.44</td><td align="center" valign="middle" >204 &#177; 64.35</td><td align="center" valign="middle" >0.303</td></tr><tr><td align="center" valign="middle" >24 h尿量(ml)</td><td align="center" valign="middle" >420 &#177; 156</td><td align="center" valign="middle" >586 &#177; 22</td><td align="center" valign="middle" >0.275</td></tr><tr><td align="center" valign="middle" >平均动脉压(mmHg)</td><td align="center" valign="middle" >80 &#177; 4</td><td align="center" valign="middle" >94 &#177; 6</td><td align="center" valign="middle" >0.107</td></tr><tr><td align="center" valign="middle" >血碳酸氢盐(mM)</td><td align="center" valign="middle" >17.00 &#177; 1.41</td><td align="center" valign="middle" >21.50 &#177; 0.71</td><td align="center" valign="middle" >0.057</td></tr><tr><td align="center" valign="middle" >血钾(mM)</td><td align="center" valign="middle" >5.20 &#177; 0.42</td><td align="center" valign="middle" >4.10 &#177; 0.28</td><td align="center" valign="middle" >0.093</td></tr><tr><td align="center" valign="middle" >血白蛋白(g/L)</td><td align="center" valign="middle" >29.00 &#177; 9.90</td><td align="center" valign="middle" >28.50 &#177; 7.78</td><td align="center" valign="middle" >0.960</td></tr><tr><td align="center" valign="middle" >CRP (mg/L)</td><td align="center" valign="middle" >21.00 &#177; 16.97</td><td align="center" valign="middle" >20.00 &#177; 9.90</td><td align="center" valign="middle" >0.950</td></tr></tbody></table></table-wrap><p>表1. 二组病人在急性肾损伤时的基线特征</p><p>图1. 顺序置入不同管径扩张管时的超声截图；① 腹直肌前鞘；② 腹直肌后鞘；③ 12Fr扩张管；④ 14.5Fr扩张管</p><p>治疗组无人出现手术相关出血、血肿、腹膜渗漏、导管引流障碍、腹腔脏器穿孔、腹透相关性腹膜炎、皮下隧道炎、出口处感染。治疗组透析前后的血葡萄糖为7.20 &#177; 0.42、7.55 &#177; 0.49 mM (P &gt; 0.05)，血白蛋白为27.50 &#177; 0.71、27.50 &#177; 2.12 g/L (P = 0.09)，血乳酸为1.05 &#177; 0.21、1.10 &#177; 0.42 (P = 0.80)。</p><p>从诊断急性肾损伤开始，治疗组与对照组的中位数生存时间分别为430、392小时(P = 0.0248)。从SOFA评分大于10分开始，治疗组与对照组的中位数生存时间分别为418、323小时(P = 0.0499)。从SOFA评分大于14分开始，治疗组与对照组的中位数生存时间分别为227、133小时(P = 0.0303)。Cox比例风险分析，治疗组死亡风险与对照组相比为0.3973 (P = 0.025)。两组的生存曲线见图2。</p></sec><sec id="s6"><title>4. 讨论</title><p>重症高龄患者急性肾损伤的治疗面临诸多困难，因为治疗本身也会带来进一步损伤。体外循环肾替代治疗需要考虑血流动力学不稳定、抗凝剂不良反应、血膜反应、滤器效能与寿命、血流感染、潜在加重脑水肿等等问题，且因设备、技术、人员等问题难以在基层医院展开。最近一项前瞻性多中心的研究发现，重症老年患者急性肾损伤的90天存活率与是否接受体外循环肾脏替代治疗没有相关性 [<xref ref-type="bibr" rid="hanspub.30492-ref6">6</xref>] 。腹透并不存在上述问题，直接穿刺法可以迅速建立透析通路，它在重症高龄患者急性肾损伤中的应用值得探讨。</p><p>B超引导下采用Seldinger法直接穿刺，顺序扩张后置入腹透管能在床旁操作，避免搬动影响或中断治疗，创伤小。全程B超介入保证了解剖层次的清晰。依次以7Fr、10Fr、12Fr、14.5Fr扩张管顺序扩张，可避免腹直肌前、后鞘阻力过大引起导管前进方向与导丝自然延伸方向成角，减少因导丝折角而撕裂腹膜的风险。而灌液试验有助于确认导丝进入腹腔。上述这些举措对减少手术相关出血、渗漏、腹腔脏器损伤、导管引流障碍，导管相关感染有着重要的作用。本研究治疗组病人无一例出现手术相关并发症。</p><p>腹透相对于体外循环的肾替代治疗来说，对血流动力学的影响更小，也不加重凝血障碍及影响血小板功能与数量，不存在血膜反应，且腹膜对中大分子的炎性介质的清除不受滤器效能与寿命影响。腹透通过减轻体内的液体负荷、纠正代谢性酸中毒、纠正电解质紊乱而改善急性肾损伤患者的内环境，并使得营养干预成为可能。因而对急性肾损伤患者的预后产生积极的影响 [<xref ref-type="bibr" rid="hanspub.30492-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.30492-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.30492-ref9">9</xref>] 。本项严格一比一配对的对照研究发现，尽管两组病人的最终结局都是死亡，但腹透能延长重症高龄患者的从诊断急性肾损伤开始的生存时间、SOFA评分大于10开始的生存时间、SOFA评分大于14开始的生存时间，这为其它治疗</p><p>图2. 两组病人的生存曲线</p><p>(如抗菌治疗)争取到了宝贵的时间。本研究治疗组死亡风险仅仅是对照组的39.73%，提示腹透对最终降低病死率有积极的作用。</p><p>当然，腹透在急性肾损伤中的应用还存在一些问题 [<xref ref-type="bibr" rid="hanspub.30492-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.30492-ref11">11</xref>] 。例如乳酸盐腹透液是否导致体内乳酸的积聚的问题。本研究未纳入严重肝衰竭的病人，治疗组血乳酸水平在治疗前后无统计学意义上的变化。而葡萄糖透析液的使用也未造成本项研究中治疗组的血糖失控，推测急性肾损伤带来的胰岛素灭活减少、能量摄入不足部分抵消了胰岛素抵抗的作用。在本项研究中，推测腹透引起的腹腔蛋白丢失增加也被营养支持的加强而抵消，因而未见有统计学意义上的透析后白蛋白水平降低。</p></sec><sec id="s7"><title>5. 结论</title><p>直穿法置入腹透管救治高龄、重症、急性肾损伤能在基层医院开展，初步严格配对研究显示有生存获益，但仍需要大样本的、前瞻性、随机对照研究去检验，且应包括本研究所未能纳入的严重肝衰竭、脓毒症的病人。</p></sec><sec id="s8"><title>文章引用</title><p>刘 玲,李铭新,杨黎明,马凌云,徐金金,蒋媛姣,袁贤忠. 直穿法置管腹透在高龄重症急性肾衰患者中的应用Acute Peritoneal Dialysis with Percutaneously Placed Catheter in Aged Intensive Care Patients with Acute Kidney Injury[J]. 临床医学进展, 2019, 09(05): 685-690. https://doi.org/10.12677/ACM.2019.95104</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30492-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Chertow, G.M., Burdick, E., Honour, M., et al. (2005) Acute Kidney Injury, Mortality, Length of Stay and Costs in Hospitalized Patients. American Society of Nephrology, 16, 3365-3370. &lt;br&gt;https://doi.org/10.1681/ASN.2004090740</mixed-citation></ref><ref id="hanspub.30492-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Joannids, M., Metnitz, B., Bauer, P., et al. (2009) Acute Kidney Injury in Critically Ill Patients Classified by AKIN versus RIFLE Using the SAPS 3 Database. Intensive Care Medicine, 35, 1692-17023.  
&lt;br&gt;https://doi.org/10.1007/s00134-009-1530-4</mixed-citation></ref><ref id="hanspub.30492-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International, 2, 1-138.</mixed-citation></ref><ref id="hanspub.30492-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cullis, B., et al. (2014) Peritoneal Dialysis for Acute Kidney Injury. Peritoneal Dialysis International, 34, 494-517.</mixed-citation></ref><ref id="hanspub.30492-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Singer, M., Deutschman, C.S., Seymour, C.W., et al. (2016) The Third International Consensus Definitions for Sepsis and Sepsis Shock (Sepsis 3). JAMA, 315, 801-810. &lt;br&gt;https://doi.org/10.1001/jama.2016.0287</mixed-citation></ref><ref id="hanspub.30492-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Barbar, S.D., Clere-Jehl, R., Bourredjem, A., et al. (2018) Timing of Renal Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. The New England Journal of Medicine, 379, 1431-1442.  
&lt;br&gt;https://doi.org/10.1056/NEJMoa1803213</mixed-citation></ref><ref id="hanspub.30492-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">George, J., Varma, S., Kumar, S., et al. (2011) Comparing Con-tinuous Venovenous Hemodiafiltration and Peritoneal Dialysis in Critically Ill Patients with Acute Kidney Injury: A Pilot Study. Peritoneal Dialysis International, 31, 422-429. &lt;br&gt;https://doi.org/10.3747/pdi.2009.00231</mixed-citation></ref><ref id="hanspub.30492-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chionh, C.Y., Ronco, C., Finkelstein, F.O., et al. (2013) Use of Peritoneal Dialysis in AKI: A Systematic Review. Clinical journal of the American Society of Nephrology, 8, 1649-1660. &lt;br&gt;https://doi.org/10.2215/CJN.01540213</mixed-citation></ref><ref id="hanspub.30492-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cullis, B., Abdelraheem, M., Abrahams, G., et al. (2014) Peritoneal Dialysis for Acute Kidney Injury. Peritoneal Dialysis In-ternational, 34, 494-517. &lt;br&gt;https://doi.org/10.3747/pdi.2013.00222</mixed-citation></ref><ref id="hanspub.30492-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ponce, D., Berbel, M.N., Regina de Goes, C., et al. (2012) High-Volume Peritoneal Dialysis in Acute Kidney Injury: Indications and Limitation. Clinical Journal of the American Society of Nephrology, 7, 887-894.  
&lt;br&gt;https://doi.org/10.2215/CJN.11131111</mixed-citation></ref><ref id="hanspub.30492-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Perl, J., Huckvale, K., Chellar, M., et al. (2009) Peritoneal Protein Clearance and Not Peritoneal Membrane Transport Status Predicts Survival in a Contemporary Cohort of Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology, 4, 1201-1206. &lt;br&gt;https://doi.org/10.2215/CJN.01910309</mixed-citation></ref></ref-list></back></article>